If you are starting Mounjaro or considering it as a weight loss treatment, understanding how the dosing schedule works is one of the most important things you can do before your first injection. Mounjaro (tirzepatide) is not taken at a single fixed dose throughout treatment. Instead, it follows a structured titration schedule, beginning at a low starting dose and increasing gradually over several months. Each step in that process matters, and each one should be guided by a qualified prescriber rather than self-managed based on social media advice or anecdotal experience.
Get in touch with our prescribing team, or complete our online consultation to find out whether Mounjaro is clinically appropriate for you.
Quick Summary
Mounjaro is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Treatment always begins at 2.5 mg for the first four weeks. Each subsequent dose increase happens at four-week intervals and should only be made with clinical oversight. The goal of titration is to find the lowest effective dose with the fewest side effects, not to reach 15 mg as quickly as possible.
Mounjaro (tirzepatide) is a once-weekly injectable prescription medication licensed in the UK for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above in the presence of at least one weight-related health condition. It is a dual GIP/GLP-1 receptor agonist, meaning it activates two separate hormone pathways simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) pathway and the glucagon-like peptide-1 (GLP-1) pathway.
This dual mechanism is what distinguishes Mounjaro from other GLP-1-only medications such as Wegovy (semaglutide). By targeting both pathways, Mounjaro produces a stronger and more sustained reduction in appetite, as well as improvements in blood glucose regulation and insulin sensitivity. Clinical trial data from the SURMOUNT-1 study showed average weight loss of up to 22.5% of body weight at the highest 15 mg dose over 72 weeks, making it the most effective weight loss injection currently licensed in the UK.
The titration schedule exists precisely because of how potent this mechanism is. Starting at a high dose immediately would cause unacceptable gastrointestinal side effects for most patients. Beginning low and increasing gradually allows the body to adapt while still delivering meaningful clinical results.
Find out how much weight you could lose using our handy calculator tool:
The standard Mounjaro titration schedule follows four-weekly intervals across six dose levels. The schedule below reflects the licensed prescribing guidance for weight management:
It is important to understand that this schedule represents the maximum rate of dose escalation. Many patients progress more slowly, particularly if they experience side effects at a given dose that require more time to settle before increasing further. Your prescriber will guide each step.
Each Mounjaro pen contains four doses (a four-week supply). Prices vary by dose strength. Below is a full breakdown of the current pricing available through our online pharmacy following a successful consultation:
Prices correct at time of publication. Each pen contains four individual doses. Prescription required following a clinical consultation.
One of the most significant risks in the current weight loss medication landscape is the volume of patients attempting to manage medication and dose increases independently, guided by social media content rather than qualified clinical advice. The Mounjaro dose schedule may appear straightforward on paper, but the decision to increase a dose involves a genuine clinical assessment of how the patient is responding to the current level, what side effects are present, and whether the overall treatment plan remains appropriate.
Mohammed Ismail Lakhi, Superintendent Pharmacist and Owner of The Care Pharmacy, makes this point directly:
“We want patients to know that health advice around weight loss medication should come from healthcare professionals and not social media algorithms. Responsible prescribing is about far more than supplying medication. Patients require suitability assessments, ongoing monitoring, education around side effects and long-term support.”
Mohammed Ismail Lakhi, MPharm, MRPharm, Superintendent Pharmacist and Owner, The Care Pharmacy
This is particularly relevant at the higher dose levels. Increasing from 2.5 mg to 5 mg carries a relatively modest incremental risk, as both are low doses and the body is still in the early adaptation phase. Moving from 10 mg to 12.5 mg, or from 12.5 mg to 15 mg, is a different clinical decision entirely. The potential for gastrointestinal side effects, changes in appetite regulation, and interactions with other medications all increase as the dose rises. These are assessments that require a prescriber, not a forum post.
Patients who access Mounjaro through our online clinic have access to ongoing prescriber reviews at every dose stage. If you are experiencing side effects that are preventing you from tolerating a dose increase, or if you are unsure whether your current dose is still appropriate, a consultation with your prescriber is always the right first step.
Gastrointestinal side effects are the most commonly reported adverse effects associated with Mounjaro, particularly during dose escalation. These include:
For most patients, these symptoms are transient and reduce significantly once the body has adjusted to a new dose level. They are most pronounced during the first one to two weeks after each increase. Practical measures that can help include:
If side effects are severe, persistent beyond two to three weeks at a given dose, or affecting your ability to eat or drink adequately, contact your prescriber before proceeding with the next scheduled dose increase. In some cases, remaining at the current dose for an additional four weeks, or temporarily reducing the dose, is the clinically appropriate response rather than pushing through.
No. The 15 mg dose represents the maximum licensed dose, not a universal target. The clinical objective of Mounjaro treatment is to achieve meaningful, sustainable weight loss with the best possible tolerability profile. For many patients, this goal is met at 10 mg or 12.5 mg, and there is no clinical rationale to increase further if adequate progress is being made and the current dose is well tolerated.
The published 22.5% average weight loss figure comes from patients on the 15 mg dose in SURMOUNT-1. Patients on lower doses in the same trial still achieved clinically significant weight loss:
These are averages across trial populations. Individual results will vary. Your prescriber will help you identify the dose level that represents the best clinical outcome for you specifically, taking your weight loss progress, tolerability, and overall health into account.
Specific questions about the Mounjaro dose schedule that our prescribing team regularly receives from patients.
The 2.5 mg dose is classified as a starting dose in the licensed prescribing guidance, not a therapeutic maintenance dose. It is not expected to produce clinically significant weight loss at this level for most patients, and remaining on it long term without escalation is unlikely to deliver meaningful outcomes. If you are tolerating it very well but concerned about side effects at higher doses, speak with your prescriber about a slower titration schedule rather than remaining at the starting dose indefinitely.
Tirzepatide has a half-life of approximately five days, and steady-state plasma concentrations are typically reached within two to four weeks at a given dose. The four-week interval allows steady-state concentrations to be fully established and gives the gastrointestinal system sufficient time to adapt before the dose is increased. Accelerating this schedule increases the risk of significant nausea and vomiting without necessarily improving efficacy outcomes.
Yes. Prior GLP-1 experience does not change the required starting dose for Mounjaro. Tirzepatide has a different receptor profile to semaglutide, and the body’s response cannot be directly predicted from prior GLP-1 tolerance alone. The licensed prescribing guidance requires initiation at 2.5 mg regardless of previous treatment history. Your prescriber may be able to progress through the titration schedule more confidently if your prior GLP-1 tolerance was good, but the starting point remains the same.
No. The absence of side effects at a given dose does not mean the body is ready for an earlier increase. Steady-state plasma concentration of tirzepatide is not reached until several weeks into treatment at any dose level. Increasing before this point means you are escalating before the full pharmacological effect of the current dose has been established, which does not serve the purpose of titration. Any change to the prescribed schedule should be discussed with your prescriber, not decided independently.
This depends on the length of the break and the dose you were on when treatment was paused. A short interruption of one to two weeks at a stable dose may not require restarting from the beginning. Longer breaks, particularly at higher dose levels, can result in a reduction in tolerance, meaning restarting at the previously established dose carries a greater risk of significant side effects. Your prescriber should always be consulted before resuming after any break of more than two consecutive doses.
Yes, and in many cases a temporary dose reduction is a more appropriate clinical response than discontinuation. If side effects at a higher dose are persistent and affecting quality of life, reducing to the previously tolerated dose for a further four weeks before attempting the increase again is a recognised prescribing approach. This should always be done in consultation with your prescriber rather than through self-adjustment, as the clinical picture needs to be reviewed as a whole before any change is made.
The recommended injection sites for Mounjaro are the abdomen, upper thigh, or upper arm. Absorption rates can vary slightly by site, with the abdomen generally offering the most consistent absorption. While the clinical significance of site variation is modest for most patients, it is advisable to rotate injection sites consistently rather than always injecting in the same location, as this reduces the risk of localised tissue reactions such as lipohypertrophy. The same rotation principle applies across all dose levels.
Mounjaro is one of the most clinically effective weight loss treatments currently available in the UK, but its effectiveness is directly tied to how well it is prescribed, monitored, and managed over time. The dose schedule is not a formality. It is a clinically designed framework that protects patients from the risks of too-rapid escalation while maximising the opportunity for meaningful, sustained weight loss.
Accessing Mounjaro through a GPhC-registered online pharmacy means every step of that process, from your initial suitability assessment to every subsequent dose review, is overseen by a qualified prescriber. This is not an inconvenience. It is the mechanism that keeps patients safe and treatment effective.
If you are ready to find out whether Mounjaro is clinically appropriate for you, contact our prescribing team directly, or complete our online consultation to get started today.
Ready to start your Mounjaro journey?
Contact us with any questions, or start your free online consultation today.
This article was written by Pharmacy Mentor and clinically reviewed by Mohammed Ismail Lakhi, MPharm, MRPharm, Superintendent Pharmacist and Owner at The Care Pharmacy. Mohammed is registered with the General Pharmaceutical Council (GPhC registration number 2072815) and leads clinical governance across the pharmacy’s weight management services.
Last reviewed: June 2026
Disclaimer: This article is for general information only and is not a substitute for individual medical advice. Always consult a qualified prescriber before starting or adjusting any prescription weight loss treatment.
Medically reviewed by
Superintendent Pharmacist
For many patients, the idea of a weekly injection is the most daunting part of starting Mounjaro. Not the dose escalation, not the dietary changes, but the simple, practical reality of administering an injection to themselves once a week, every week, for months. The good news is that with the right technique and a good […]
Starting a new prescription medication always comes with questions. When that medication is as clinically potent as Mounjaro (tirzepatide), those questions tend to centre on one thing above all else: the side effects. What will they feel like? When will they start? And, perhaps most importantly, how long do Mounjaro side effects last? This guide […]
If you have recently started Mounjaro and noticed a dip in your energy levels, you are not alone. Fatigue is one of the most commonly reported experiences during the early weeks of treatment, but the cause is not always the medication itself. So, does Mounjaro make you tired, or is something else going on? The […]
The most common question we hear from patients is: Wegovy vs Mounjaro — which one should I choose? This honest, pharmacist-written guide covers clinical trial data, the new Wegovy 7.2mg dose, real-world UK pricing, side effects, NHS access, and how to decide which weight loss injection suits your goals. Updated: March 2026 · 16 min […]
Mounjaro Price Comparison UK Guide · Updated March 2026 The same pen. The same manufacturer. Up to £100/month difference in price depending on where you buy it. This is the most comprehensive Mounjaro price comparison UK guide available — every dose, every hidden cost, NHS vs private access, and how to buy safely from a […]
Mounjaro is an effective medical weight loss treatment that helps regulate appetite and improve blood sugar balance. While the medication can reduce hunger and increase feelings of fullness, long term success depends heavily on the structure of your diet. Knowing how to build a diet plan that complements your Mounjaro weight loss journey can help […]
